Related Experiment Video
Updated: Mar 31, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Regimens for the Hepatitis C Treatment-Naive Patient
1Department of Gastroenterology, Cedars Sinai Medical Center, 8730 Alden Drive, Suite E235, Los Angeles, CA 90048, USA; Liver Transplant Program, Cedars Sinai Medical Center, 8900 Beverly Boulevard, Suite 250, Los Angeles, CA 90048, USA.
Abstract:
Hepatitis C virus (HCV) infection is a leading cause of cirrhosis and hepatocellular carcinoma, globally. Most individuals infected with HCV are asymptomatic. The introduction of the newer direct-acting antiviral (DAA) therapies has led to achievement of treatment success rates of more than 90%. Sustained virologic response is the end point of therapy, and is considered a virologic cure. It is defined as undetectable HCV RNA 12 weeks after end of therapy. This article reviews current approved non-interferon-based therapy and data from clinical trials in treatment-naive patients with chronic HCV infection.
Related Concept Videos
Hepatitis
Retrovirus Life Cycles
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Treatment Resistent Cancers
Pharmaceutical Poisoning: Treatment Strategies

